E-ISSN: 2788-9270
P-ISSN: 2788-9262
NJPS 2021; 1(2): 40-48
Received: 11-05-2021
Accepted: 12-06-2021

Devendra Singh Lodhi
Gyan Ganga Institute of Technology & Sciences, Bargi Hills Jabalpur, Madhya Pradesh, India

Megha Verma
Gyan Ganga Institute of Technology & Sciences, Bargi Hills Jabalpur, Madhya Pradesh, India

Pradeep Golani
Gyan Ganga Institute of Technology & Sciences, Bargi Hills Jabalpur, Madhya Pradesh, India

Pradeep Patra
School of Pharmacy SSSUTMS, Opposite Oil fed plant Pachama, Sehore, Madhya Pradesh, India

Sanjay Nagdev
Shri. Prakashchand Jain College of pharmacy and Research Plot No. 82/1/2, Street No. 185, Palaskhede Bk. Jamner, Jalgaon, Maharashtra, India

Akash Singh Pawar
Institute of Pharmaceutical Sciences, SAGE University Indore, Madhya Pradesh, India

Correspondence
Devendra Singh Lodhi
Gyan Ganga Institute of Technology & Sciences, Bargi Hills Jabalpur, Madhya Pradesh, India

Fast-dissolving oral film of anti-migraine drug: A review

Devendra Singh Lodhi, Megha Verma, Pradeep Golani, Pradeep Patra, Sanjay Nagdev and Akash Singh Pawar

Abstract
Patient suffering from Migraine with nausea, vomiting, and sensitivity to light/sound be given an oral film of the drug Anti -Migraine Drug to relieve and ease their pain. An intense headache that is prone to recurrence, especially in women. A week is the most common, but it can also happen once every few years or less often. A few hours to three days, depending on the severity of the injury. In general, morning headaches affect only one side of the head, typically the forehead side. Headaches, which can be extremely painful, are very common. These conditions are the most common causes of headaches, accounting for 95 percent or more of all complaints. Based on the transdermal patch technology, mouth dissolving films are a new drug delivery system for oral delivery of drugs. When a patient's tongue or any other mucosal tissue is wetted by saliva, a thin oral strip is placed on the patient's tongue or mucosal tissue, which quickly hydrates and sticks to the application site. Upon swallowing it, it rapidly disintegrates and dissolves, releasing the medication for oro-mucosal absorption. Unlike other existing, the rapid films can be produced at a cost comparable to that of conventional tablets using fast-dissolving films to deliver anti-migraine drugs for migraine treatment is a novel and promising approach.

Keywords: Migraine, fast dissolving, oral film, oral strip, NDDS, oral patch

Introduction
Oral route of medication is a most favoured dosage form because of its simplicity of organization, non-obtrusiveness, flexibility, patient consistence and agreeableness. With respect to course of medication organization, many substitutes have ceaselessly been introduced by utilizing late clever advances for paediatrics, geriatrics, queasy and rebelliousness patients. Bio adhesive mucosal measurement structures including glue tablets, gels and fixes are results of mechanical turn of events. Among different dose frames, the utilization of polymeric movies for conveying prescription into buccal hole has created incredible potential in ongoing period. Orally breaking down films (ODFs), when put on tongue, quickly hydrates by dousing salivation following deterioration and additionally disintegration delivering dynamic drug specialist from the measurements structure.. ODFs are somewhat plans which are ordinarily pre-arranged utilizing hydrophilic polymers empowering fast disintegration upon contact with salivation. Oral deteriorating tablets (ODTs) and oral crumbling films (ODFs) are the common instances of orally breaking down drug conveyance frameworks. These frameworks were created in late 1970 to fill in as an option in contrast to customary measurements structures, for example, quick breaking down tablets and cases for geriatrics and pediatric patients experiencing issues in gulping regular dose structures. A normal ODF is generally equivalent to the size of a postage stamp. In commercial center, the presentation of ODT was firmly connected with advising of patients about the suitable organization by giving guidance like "don't bite/don't swallow". Nonetheless, disregarding these guidelines, occurrences in regards to biting and gulping were frequently revealed. In any case, ODFs loosened the majority from these unfavourable occasions'. Solid dosage form accounts for approximately 60% of all formulations. Tablets are the most commonly used dosage form due to their portability, suitability, cost effectiveness, and ease of administration [1]. However, there are disadvantages to oral drug administration, such as liver degradation and enzymatic degradation in the gastrointestinal tract, which prevent oral administration of many types of drugs, particularly peptides and proteins.

Discussion: One of the suggested routes for systemic drug delivery appears to be the buccal area of the oral mucosal cavity.

One of the suggested drug delivery pathways appears to be the buccal area of the oral mucosa. An inhibitor of hepatic first pass metabolism is used. Mouth-dissolving films [2]. As a result of the desire to provide patients with more conventional methods of taking their medication, the concept of orally disintegrating dosage forms was born. An interesting trend has emerged in recent years: the demand for ODT has skyrocketed, especially among elderly and paediatric patients who have trouble swallowing conventional tablets and capsules. The result is a high incidence of ineffective therapy [3]. On the basis of the transdermal patch technology, mouth dissolving films were created. Patients simply place the mouth dissolving films on their tongue or any other oral surface.

The Advantages of fast dissolving films [4, 5]

- As a result, the film should be elegantly thin.
- Films come in different sizes and shapes.
- It should not be obstructive in its nature.
- It should be able to cling to the mouth cavity without much difficulty;
- Disintegration without water and rapid medication release are two of the most notable features.
- Dosing convenience.
- There is no requirement for water to be used.
- There's no risk of choking on the food.
- Masking the taste
- An increase in the stability of the product.
- Patient compliance is improved.
- With a reduced first-pass hepatic effect, the drug enters the systemic circulatory system.
- Location-specific, locally-based action
- If you're interested in finding out more about our products, please contact us.

Comparatively, the syrup has a better dose accuracy.

Fast Dissolve Technology Classification [6]. Technologies that dissolve quickly can be divided into three broad categories [Table 1].

1. Systems lyophilized
2. Intuitive tablet-based solutions
3. Thin films for use in the oral cavity

- **Systems lyophilized:** Systems that are lyophilized. An excipient is added to a drug suspension or solution in a mould or blister pack to create a tablet-shaped unit. They are then frozen and lyophilized in a pack or mould, before being used. Because of the high porosity of the units, water or saliva can easily penetrate and disintegrate them.

- **Intuitive tablet-based solutions:** Systems based on tablet computers that have been compressed. This system is produced using the standard tablet technology by direct compression of excipient. Tablet technologies vary in hardness and friability depending on how they are made and how they are used. For fast-dissolve tablets, water-soluble excipient, super-disintegrates, or effervescent components are used in the formulation, allowing water to penetrate rapidly into the tablet's core.

- **The use of oral thin films:** Oral wafers are another name for it. In the past few years, oral thin films have evolved into breath strips in the confection and oral care markets. Vitamins and personal care products can now be delivered to consumers in a novel and widely accepted form. They are a proven and accepted technology for systemic delivery of APIs for OTC medications. There are many different stages of drug development for prescription drugs. Listerine Pocket Packs, a popular mouthwash in the United States, have been credited with this. In such systems, hydrophilic polymers are used to create a 50-200 mm film. As a large sheet of film, the film is manufactured and then cut into individual dosage units for packaging in a variety of pharmaceutically acceptable format options.

Table 1: Three types of oral films are differentiated from each other

Type /Property	Flash Release Wafer	Mucoadhesive Melt-away wafer	Mucoadhesive Sustained release Wafer
Area (cm2)	2-8	2-7	2-4
Thickness (μm)	20 – 70	50 – 500	50 – 250
Structure	Film: single layer	Single or multilayer system	Multilayer System
Excipients	Hydrophilic polymers	Hydrophilic polymers	Low / Non-soluble polymers
Drug phase	Solid solution	Solid solution or suspension	Suspension or solid solution
Application	Tongue (upper palate)	Gingival or buccal region	Gingival or other region in oral cavity
Dissolution	Maximum 60 seconds	Disintegration in a few minutes, forming gel	Maximum 8 – 10 hr.

Selecting a drug's ideal characteristics [8]

• The drug's taste should be pleasant.

• Preferably, the drug should have a dose of 40 mg or more. A small or moderate molecular weight is ideal.

Drugs should be stable and soluble in water as well as in saliva.

In the oral cavity, it should be partially unionised, depending on the pH.

• It should be able to permeate oral mucosa (gum tissue)

Formulation aspects for fast dissolving films [9]

1. Drug Category
2. Film Forming Polymers
3. Plasticizers
4. Sweetening Agents
5. Saliva Stimulating Agents
6. Cooling Agent
7. Flavoring Agent
8. Coloring Agent
9. Surfactants
10. Stabilizing and thickening specialists

Definitions of FDOFs having the qualities, for example, taste concealing, quick dissolution, physical appearance, mouth feel and so on All excipients utilized in the plan of FDOF ought to be Generally Regarded as Safe (for example GRAS-recorded) and ought to be endorsed for use in oral drug dose structures.

1. **Medication Category:** This innovation has the potential for conveyance of assortment of APIs. Notwithstanding, there are a few restrictions like the size of the dose structure, drugs having high portion are hard to be joined in films. A few classes of medications can be planned as quick dissolving films including antiulcer, antiasthamatics, antitussives, expectorants, antihistaminics, NSAID'S and so on

2. **Film Forming Polymers:** Water-dissolvable polymers are utilized as film formers as they give quick breaking down, great mouth feel and mechanical solidarity to the movies. The power of the strip relies upon the sort of polymer and its sum in the definitions. Water-solvent polymers film sticks to the bucosal mucosa and quickly conveys drug into the fundamental flow. Different polymers are accessible for planning of movies of which pullulan, gelatine and hypromellose are most regularly utilized. For the most part, 45%w/w of polymer ought to be available in the absolute load of dry film. Instances of water-dissolvable polymers include: Pullulan, Gelatin, guargum, Xanthum gum, Hydroxyl propyl methyl cellulose, Modified starches, Hydroxyl ethyl cellulose.

3. **Plasticizers:** It is a fundamental element of the oral movies. The choice of plasticizer relies on its similarity with the polymer and furthermore the kind of dissolvable utilized in the projecting of film. It works on the adaptability of the film and decreases the weakness of the film. The strip properties of Plasticizer are fundamentally improved by lessening the glass progress temperature of the polymer. They are utilized in the convergence of 1 - 20%w/w of dry polymer weight. Models include: Glycerol, Propylene glycol, Low atomic weight polyethylene glycols, Citrate subsidiaries like triacetin, acetylcitrate, and Phthalate subordinates like dimethyl, diethyl, dibutyl subordinates, and Castor oil.

4. **Improving specialists** Sugars are the significant piece of the food items just as drug items. If there should arise an occurrence of oral dose structure the sweet desire for plan is more significant particularly for pediatric populace. In this way, to work on the satisfactoriness of the mouth dissolving plans Natural sugars just as fake sugars are utilized. Following are the sugars which are Suitable in FDF plan: (a) Water solvent normal sugar: xylose, ribose, glucose, sucrose, maltose, stevioside.
- Water dissolvable fake sugar: sodium or calcium saccharin salts, cyclamate salts, acesulfame-k.
- Dipeptide based sugar: aspartame

5. **Salivation invigorating specialist:** The salivation invigorating specialists are utilized to build the pace of creation of spit that is useful in the quicker disintegration of the film plans. For the most part acids which are utilized in the arrangement of food can be used as salivary energizers. Instances of salivary energizers are as per the following: Citric corrosive, malic corrosive, lactic corrosive, ascorbic corrosive and tartaric corrosive and so on Among these citrus extract is most favored salivation invigorating specialist in the plan.

6. **Cooling specialists:** Môn methyl succinate is utilized as cooling specialists which assists with further developing the flavour strength and to upgrade the mouth-feel impact of the item. Other cooling specialists like WS3, WS23 and Utracoll II can likewise be utilized related to flavours.

7. **vii. Enhancing specialists:** Insight for the flavour changes from one individual to another contingent upon the identity and preferring. It was seen that age assumes a huge part in the taste affection. Manufactured flavour oils, oleo saps, separate got from different pieces of the plants like leaves; products of the soil are utilized for choice of enhancing specialist. Instances of flavour oils are Peppermint oil, cinnamon oil, oil of nutmeg. While vanilla, cocoa, espresso, chocolate and citrus are instances of fruity flavours. Not many instances of natural product pith type are Apple, raspberry, cherry, pineapple. The measure of flavor expected to cover the taste relies upon the flavor type and its solidarity.

8. **Shading specialists:** Titanium dioxide or FD&C supported shading specialists are joined (not surpassing fixation levels of 1%w/w) in FDF definition when a portion of the detailing fixings or medications are available in insoluble or suspension structure.

9. **Surfactants:** Surfactants are utilized as solubilising or wetting or scattering specialist. By the utilization of surfactant the film gets broken down in practically no time and delivery dynamic specialist right away. Dissolvability of inadequately solvent medications in quick dissolving oral movies can be improved by utilizing surfactant. A portion of the models are polaxamer 407, sodiumlauryl sulfate, benzalkonium chloride, benzthonium chloride, tweens.

10. **Settling and thickening specialists**
For the most part, to work on the thickness and consistency of scattering or arrangement of the film planning the settling and thickening specialists are utilized prior to projecting. Normal gums like thickener, insect bean gum, carragenan and cellulosic subsidiaries are not many instances of balancing out and thickening specialists. They are utilized in the focus up to 5%w/w.

Approaches utilized for the definition of quick dissolving films [10 [Figure 01]

Ordinary methodologies

1. Dissolvable projecting technique
2. Hot soften expulsion
3. Semisolid projecting
4. Strong scattering expulsion
5. Rolling.



Fig 1: Approaches used for the formulation of fast dissolving films [Md erfan *et al*.] [10]

Recently, fast dissolving films are gaining interest as an alternative of fast dissolving tablets. The films are designed to dissolve upon contact with a wet surface, such as the tongue, within a few seconds, meaning the consumer can take the product without need for additional some of marketed formulation are listed [Table No.2].

Table 2: Marketed Fast Dissolving Oral Film

Product	Manufacturer	Active Pharmaceutical Agent	Strength(mg)
Triaminic	Novartis	Dextromethorphan HBr	7.5
Triaminic	Novartis	Diphenhydramine HCl	12.5
Triaminic	Novartis	Dextromethorphan HBr	15
Gas-X	Novartis	Simethicone	62.5
Sudafed	Pfizer	Phenylephrine HCl	10
Benadryl	Pfizer	Diphenhydramine HCl	12.5
Chloraseptic	Prestige	Benzocaine Menthol	3/3
Suppress	InnoZen	Menthol	2.5
Orajel	Del	Menthol/Pectin	2/30
Listerine	Pfizer	Cool mint	

ANTI-Migraine Drug [11]: Anti-migraine drugs are meds used to forestall or diminish the seriousness of headache migraines. There is a significant socioeconomic burden associated with migraine, which is a common and disabling primary headache disorder. Acute and preventive strategies are used to treat migraines, with a variety of treatment options. This treatment's goal is to restore function quickly, with minimal recurrence, and with minimal side effects. It is important to note that pharmacological treatment is determined on an individual basis, taking into account the patient's medical history, migraine attack characteristics, and treatment preferences. The pharmacodynamic and pharmacokinetic properties of various drugs. Headache is a profoundly impairing essential cerebral pain issue with a 1-year commonness of ~15% in the general population1, [2]. As per the Global Burden of Disease Study, headache is the second most common neurological problem worldwide and is answerable for more incapacity than any remaining neurological issues combined [12, 13]. Headache shows clinically as intermittent assaults of migraine with a scope of going with symptoms4. In around 33% of people with headache, cerebral pain is now and again or consistently went before or joined by transient neurological unsettling influences, alluded to as headache aura [14, 15]. Besides, a minority of those influenced foster ongoing headache, where assaults become profoundly frequent. The pathogenesis of headache is broadly accepted to include fringe and focal initiation of the trigemino vascular system, and cortical spreading misery is believed to be the fundamental neurophysiological substrate of headache aura [9]. Nonetheless, much remaining parts obscure about explicit pathogenic cycles and hardly any system based treatment choices as of now exist [16]. Medicines for headache incorporate intense and preventive prescriptions and a scope of non-pharmacological therapies. Regardless of these treatment choices and the thorough demonstrative measures, clinical consideration remains problematic — misdiagnosis and under-treatment of headache are significant general wellbeing challenges [17]. Populace based information from Europe demonstrate that preventive prescription for headache is utilized by just 2–14% of qualified individuals [19], a disturbing finding that calls for worldwide action [18]. A complete methodology is expected to work with exact conclusion and proof based administration. In this Consensus Statement, we give a ten-venture way to deal with the determination and the executives of headache [Fig.2] Improvement of this methodology was started by the Danish Headache Society, and the Consensus Statement is embraced by the European Headache Federation (EHF) and the European Academy of Neurology (EAN). The point of the methodology is to help care and clinical dynamic by essential consideration experts, nervous system specialists and migraine experts the same.



Fig 2: There is ten steps to diagnosing and treating migraines

Stage 1: When to presume headache: In the third release of the International Classification of Headache Disorders (ICHD-3), headache is characterized into three principle types [4]: headache without quality, headache with emanation, and constant headache. The clinical qualities of each should be considered to guarantee an exact analysis. Headache without emanation Headache without emanation is described by repetitive migraine assaults that last 4–72 h4. Regular elements of an assault incorporate a one-sided area, throbbing quality, moderate or serious torment force, and disturbance by routine physical activity [4, 13]. In any case, reciprocal torment isn't unprecedented; populace based

information demonstrate that ~40% of people with headache report respective torment during attacks [5]. The most widely recognized related manifestations are photophobia, phonophobia, sickness and vomiting [4, 13]. Prior to the beginning of torment, prodromal side effects can incorporate a discouraged state of mind, yawning, weariness and yearnings for explicit foods [14]. After goal of the migraine, postdromal side effects can last up to 48 h and regularly incorporate sleepiness, focus challenges and neck stiffness [15].

Headache with quality: Around 33% of people with headache experience aura5, either with each assault or for certain assaults. Air is characterized as transient central neurological manifestations that normally go before, yet at times go with, the cerebral pain period of a headache attack [4]. In >90% of influenced people, air shows visually [4, 16], traditionally as fortress spectra4. Tactile manifestations happen in ~31% of influenced people and are normally capable as dominatingly one-sided paraesthesia (a tingling sensation or potentially deadness) that spreads bit by bit in the face or arm16. More uncommon air manifestations incorporate aphasic discourse aggravation, brainstem side effects (like dysarthria and dizziness), engine shortcoming (in hemiplegic headache) and retinal indications (for instance, rehashed monocular visual disturbances) [4]. Quality side effects can be like those of transient ischaemic assaults (TIA), yet can be separated on the premise that emanation indications frequently spread slowly (over ≥5 min) and happen in progression, though manifestations of a TIA have an abrupt, concurrent onset [4]. Remarkably, headache with atmosphere and headache without air can coincide. Numerous people with headache with atmosphere additionally experience assaults that are not gone before by aura4. In such cases, headache with air and headache without emanation ought to both be analyzed.

Persistent headache Constant headache is characterized as ≥15 cerebral pain days of the month for >3 months and satisfaction of ICHD-3 rules for headache on ≥8 days per month4. Constant headache is definitely not a static substance and inversion to rambling headache isn't uncommon. Additionally, retransformation to ongoing headache cans hence occur [17].

Family background of headache Headache has a solid hereditary segment and its predominance is higher among individuals with straightforwardly influenced first-degree family members than among the general population [18, 19]. Family ancestry is, accordingly, a significant piece of the clinical history and is frequently sure in patients with headache, despite the fact that it very well may be under-revealed by patients [20].

Suggestions Suspect headache without air in an individual with intermittent moderate to extreme migraine, especially in case torment is one-sided or potentially throbbing, and when the individual has going with manifestations like photophobia, phonophobia, queasiness and additionally regurgitating.

Suspect headache with air in an individual with the manifestations above and repetitive, short-enduring visual or potentially hemisensory unsettling influences. Suspect constant headache in an individual with ≥15 migraine days out of each month. Doubt of headache ought to be reinforced by a family background of headache and if beginning of manifestations is at or around adolescence.

Stage 2: Diagnosis of headache

The clinical history is the pillar of headache determination; with the help of a scope of distributed guides (see the part Diagnostic guides), a full history should empower deliberate use of the measures set out in the ICHD-3. Actual assessment is frequently corroborative and further examinations (for instance, neuroimaging, blood tests or lumbar cut) are infrequently needed to validate or dismiss intuitions of auxiliary foundations for cerebral pain.

Clinical history A satisfactory clinical history should incorporate essentially the accompanying: age at beginning of migraine; length of migraine scenes; recurrence of cerebral pain scenes; torment attributes (for instance, area, quality, seriousness, disturbing elements and soothing variables); going with side effects (for instance, photophobia, phonophobia, sickness and regurgitating); atmosphere manifestations (assuming any); and history of intense and preventive prescription use. All are fundamental for the utilization of the ICHD-3 models.

Indicative models The ICHD-3 criteria4 (Box 1), which were created by the International Headache Society, set out the clinical elements that build up the analysis of headache and its sorts and subtypes. These standards focus on particularity over affectability, so an extra arrangement of measures are given for a determination of plausible headache, which is characterized as "headache like assaults missing one of the elements needed to satisfy all rules for a kind or subtype of migraine"4. Likely headache is a determination forthcoming affirmation during early development.

Headache without air

1. No less than five assaults that satisfy rules 2–5
2. Cerebral pain assaults that last 4–72 h when untreated or ineffectively treated
3. Migraine has something like two of the accompanying four attributes: one-sided area throbbing quality moderate or serious torment power exacerbation by, or causing evasion of, routine actual work (for instance, strolling or climbing steps)
4. Something like one of the accompanying during the cerebral pain: sickness or potentially retching photophobia and phonophobia
5. Worse represented by another ICHD-3 finding

Headache with quality

1. Somewhere around two assaults that satisfy measures 2 and 3
2. At least one of the accompanying completely reversible air side effects: visual tactile discourse as well as language engine brainstem retinal
3. Somewhere around three of the accompanying six qualities:
4. somewhere around one emanation side effect spreads bit by bit over ≥5 min at least two emanation indications happen in progression every individual emanation indication keeps going 5–60 min somewhere

around one emanation side effect is one-sided somewhere around one emanation side effect is positive the air is went with or followed by cerebral pain inside 60 min
5. Worse represented by another ICHD-3 conclusion

Constant headache
1. Cerebral pain (headache like or pressure type-like) on ≥15 days/month for >3 months that satisfy measures 2 and 3
2. Assaults happen in a had no less than five person assaults that satisfy the measures for headache without emanation and additionally for headache with atmosphere.
3. On ≥8 days/month for >3 months, any of the accompanying measures are met: rules 3 and 4 for headache without emanation rules 2 and 3 for headache with emanation accepted by the patient to be headache at beginning and diminished by a triptan or ergot subsidiary
4. Worse represented by another ICHD-3 analysis

Drug abuse cerebral pain
1. Migraine on ≥15 days/month in a person with a prior cerebral pain problem
2. Customary abuse for >3 long periods of at least one medications that can be taken for intense or potentially suggestive therapy of cerebral pain (ordinary admission of at least one non-narcotic analgesics on ≥15 days/month for ≥3 months or some other intense drug or mix of prescriptions on ≥10 days/month for ≥3 months)
3. Worse represented by another ICHD-3 analysis Migraine journals are helpful demonstrative guides that can likewise be utilized to reconsider the determination at whatever point required (Box 2). Day by day journal sections record data on the example and recurrence of cerebral pains and its going with side effects (for instance, queasiness, photophobia and phonophobia), just as utilization of intense prescriptions (Box 2). Journals ought not to be conflated with migraine schedules, which normally incorporate less data yet are helpful in the subsequent evaluation of patients. Cerebral pain schedules ought to be utilized to record, at least, the recurrence of headache, the recurrence and power of migraines, and migraine related occasions, for example, intense and preventive drug use and monthly cycle. The rise and refinement of electronic cerebral pain journals and schedules are significant turns of events, as these are probably going to work with obtaining of more nitty gritty data without uniquely compromising consistence. Consistence with migraine journals can be an issue, especially in essential consideration; for instance, in one populace based investigation of patients who detailed regular cerebral pains, just 46% of members finished the study [21].

Determination of headache can likewise be worked with by utilization of screening instruments that assess whether a patient's clinical elements propose headache (Box 2). After utilization of such screening instruments, finding ought to be affirmed by a survey of the clinical history as well as utilization of a symptomatic cerebral pain journal. Approved screening instruments incorporate the three-thing ID-Migraine questionnaire [22] and the five-thing Migraine Screen Questionnaire (MS-Q) [23]. The ID-Migraine poll has an affectability of 0.81, a particularity of 0.75 and a positive prescient worth of 0.93 when contrasted and ICHD-based analysis by a cerebral pain specialist [22]. The MS-Q instrument has an affectability of 0.93, an explicitness of 0.81 and a positive prescient worth of 0.83 [23]. The two instruments have been deciphered and approved for use in a few languages [24. 25, 26, 27]. Cerebral pain journals are helpful demonstrative guides and can likewise, if necessary, help with re-assessment of determination at subsequent meet-ups.

Conclusions

This study indicates that anti migraine drug is One of the novel approaches in the field of pharmaceutical sciences are oral fast disintegrating films. With no risk of choking and better safety and efficacy than conventional forms, they have improved patient acceptance as well as patient compliance. ODFs were developed to help patients with dysphasia that had difficulty swallowing conventional oral dosage forms. There are a variety of ODFs available today for conditions such as hypertension and acidity. Their administration without the use of water fulfils the population seeking ease in drug administration, as well as bypassing hepatic metabolism, leading to better therapeutic response. It will be beneficial for patient.

References

1. Honey Goel, Parshuram Rai, Vikas Rana, Ashok K. Tiwary. Orally Disintegrating Systems: Innovations in Formulation and Technology. Recent Patents On Drug Delivery &Formulation 2008;2:258-274.
2. Arun Arya, Amrish Chandra, Vijay Sharma, Kamla Pathak. Fast Dissolving Oral Films: An Innovative Drug Delivery System And Dosage Form, International Journal of Chem tech Research 2010;2:576-583.
3. Thakur Smriti. Mouth Dissolving Films: A Review, International Journal Of Pharma And Bio Sciences 2013;4(1):899-908.
4. Bhyan B, Jangra S, Kaur M, Singh H. Orally Fast Dissolving Films: Innovations In Formulation And Technology. Int J Pharm Sci Rev Res 2011;9:506.
5. Bhura N, Sanghivi K, Patel U, Parmar B. A Review on Fast Dissolving Film. Int J Res Bio Sci 2012;3:66-9.
6. Aggarwal J, Singh G, Saini S, Rana AC. Fast Dissolving Films: A Novel Approach To Oral Drug Delivery. Int. Res. J Of Pharm 2011;2(12):69-74.
7. Mahajan A, Chhabra N, Aggarwal G. A Formulation and Characterization of Fast Dissolving Buccal Films: A Review. Scholars Res. Library Der Pharmacia Lettre 2011;3(1):152-165l.
8. Arya A, Chandra A, Sharma V, Pathak K. Fast Dissolving Oral Films: An Innovative Drug Delivery System and Dosage Form. Int. J of Chemtech. Res 2010;2(1):576-583.
9. Soni MM, Patel KR. Formulation and evaluation of fast dissolving film of lurasidone Hcl. Int. J Pharm. Res. Bio. Sci 2016;5(2):101-123.
10. Pathan A, Gupta MK, Jain NK, Dubey A, Agarwal A. Formulation and evaluation of fast dissolving oral film of promethazine hydrochloride using different surfactant. J. Innov. Pharm. Bio. Sci 2016;3(1):74-84.
11. Nair SS, Padamanabhan R, Sreena K. Development and Evaluation of fast dissolving oral thin film containing

prochlorperazine maleate. Eur. J Pharm. Medical Res. 2016;3(1):379-384.
12. Newton AMJ, Rani SM, Sukhjinder K. Fabrication and evaluation of fast disintegrating oral hybrid films of propranolol hydrochloride by using pectin and synthetic polymers. J Dev. Drugs 2016;5(2):157.
13. Reddy S, Devi S, Naik V, Mounica NVN, Rao AA. Formulation and evaluation of fast dissolving buccal films conaining zolmitriptan. Int. J Pharm. chem. Res 2016;1(1):129-140.
14. Patil JS, Deokar AB, Vilegave KV, Morani DO, Dhadde SB. Design, evaluation and characterization of rapidly dissolving oral strips of metoprolol succinate. J Pharm. Analy. Insights 2016;1(2):1-6.
15. Haque SE, Sheela A. Development of polymer-bound fast-dissolving metformin buccal film with disintegrants. Int. J Nanomedicine 2015;10(1):199-205.
16. Thakur S, Raju L, Soni A, Agnihotri B. Formulation and evaluation of fast dissolving film of losartan potassium. World J Pharmcol. Res. Tech 2015;3(6):179-189.
17. Sri Rekha M, Sultana SKS, Mahathi K, Parveen P, Prathima B, Devi AS. Formulation and evaluation of fast dissolving buccal film containing isradipine solid dispersion. Amer. J Pharmtech. Res 2015;5(2):221-247.
18. Pawar SV, Junagade MS. Formulation and evaluation of mouth dissolving film of risperidone. Int. J Pharm Tech. Res 2015;8(6):218-230.
19. Jelvehgaril M, Montazam SH, Soltani S, Mohammadi R, Azar K, Montazam SA. Fast dissolving oral thin film drug delivery systems consist of ergotamine tartrate and caffeine anhydrous. Pharm. Sci 2015;21:102-110.
20. Goutam K, Garg R, Sharma A, Singh A, Sharma P, Kaushal S. Formulation and evaluation of oral fast dissolving films of promethazine theoclate. Indo. Ameri. J Pharm. Res 2015;5(8):2536-2544.
21. Mundada AS, Jain RA. Formulation, development and optimization of fast dissolving oral film of montelukast sodium. Int. J Drug Dev. Res 2015;7(4):40-46.
22. Dwivedy BN, Dabral P, Kumar R. Preparation and evaluation of mouth dissolving film of pantoprazole sodium. World J Pharm. Pharmceut. Sci 2014;3(8):1564-1576.
23. Kumar R, Pandey GS, Sharma R, Singh Y, Teotia UVS. Effects of maltodextrin and glycerin on mechanical properties of oral fast dissolving film of salbutamol sulphate. Int. J Adv. Pharm. Bio. Chem 2014;3(1):199-209.
24. Saleem MA, Jahangir MA, Patel HR, Kazmi I, Muheem A, Ahmad K. Formulation and evaluation of fast dissolving films of levocetirizine. World J Pharm. Pharmceut. Sci 2014;3(9):1310-1323.
25. Prabhu P, Dubey A, kamath K. formulation and Evaluation of fast-dissolving films of lisinopril. Egyp. Pharm. J 2015;14:56-64.
26. Swamy NGN, Kumar SS. Formulation and evaluation of fast dissolving oral films of palonosetron hydrochloride using Hpmc-E5.Int. J Pharm. Chem. Sci 2014;3(1):145-150.
27. Pandey P, Chauhan S. Fast dissolving sublingual films of zolmitriptan: A novel approach for migraine attacks. Ind. J. Pharm. Edu. Res 2014;48(1):67-72.
28. Deepthi A, Reddy V, Navaneetha K. Formulation and evaluation of fast dissolving oral films of zolmitriptan. Ameri. J Adv. Drug Deliv 2014;2(2):153-163.
29. Kumar SK, Nagabhushanam MV, Sambasiva Rao KRS, Bhikshapathi DVRN. Formulation development and in vivo evaluation of zolmitriptan oral dissolving films. Int. J Pharm. Bio. Sci 2013;4(3):638-654.
30. Patel HJ, Patel PB, Kamdar KM, Patel KB, Shah AA, Patel ZP. Development and optimization of fast dissolving film of losartan potassium. Amer. J. Pharm. Health Res 2013;1(2):35-44.
31. Kathpalia H, Sule B, Gupte A. Development and Evaluation of Orally Disintegrating Film of Tramadol Hydrochloride. Asian Journal of biomedical and pharmaceutical sciences 2013;3(24):27-32.
32. Bansal G, Garg V, Siddiqui MD. Investigation of polymers alone and in combination for the development of oral thin film. Int. J. Inv. Pharm. Sci 2013;1(3):31-235.
33. Albert AA, Serjeant EP. Ionization constants of Acids and Bases. Wiley, Newyork, 1984.
34. Yalkowiski SH, Roseman TJ. Techniques of solubilisation of Drugs, Chapter 3, ed. S.H. Yalkowski Marcel Dekker, Newy, 1981.
35. Indian pharmacopeia 2007, 4.
36. European Pharmacopoeia. Directorate for the Quality of Medicines of the Council of Europe (EDQM) 2004;1:628.
37. PK Lakshmi, Sreekanth J, Aishwarya Sridharan. "Formulation development of fast releasing oral thin films of Cetriizine dihydrochloride with Eudagrit EPO nad optimization through Taguchi orthogonal Experimental design", Asian journal of pharmaceutical Sciences, 2005.
38. Patel AR, Dharmendra S, Jignyasha P, Raval A. Fast dissolving films (FDFS) as a newer venture in fast dissolving dosage forms. Int J Drug Deliv Res 2010;2:232-46
39. Barnhart S, Rathborne M, Hadgraft J, Roberts M, Lane M. Thin film oral dosage forms, in: Modified release drug delivery technology 2nd edition, Drugs and the Pharmaceutical Sci 209-216.
40. Nishimura M, Matsuura K, Tsukioka T, Yamashita HN, Inagaki Sugiyama T. *In vitro* and *in vivo* characteristics of prochlorperazine oral disintegrating film, International J Pharmaceutics 2009;368(1-2):98-102.
41. Jayjock E. Robert Schmitt, Chilling Chein, Gloria Tirol, "Determination Of fast dissolve Oral Film Dissolution Rate via Conductivity" The Dow Chemical Company 2005.
42. Yellanki SK, Jagtap S, Masareddy R. "Dissofilm: a novel approach for delivery of phenobarbital; design and characterization," Journal of Young Pharmacists 2011;3(3):181-188.
43. Joshi P, Patel H, Patel V, Panchal R. "Formulation development and evaluation of mouth dissolving film of domperidone," Journal of Pharmacy and Bioallied Sciences, 2012;4(5):S108-S109.
44. Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008039 2013.
45. Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2, CD008783 2012.

46. Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008040 2013.
47. Goadsby PJ *et al*. Early vs. non-early intervention in acute migraine – 'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008;28:383-391.
48. Lantéri-Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia 2012;32:226-235.
49. Färkkilä M *et al*. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463-471.
50. Dahlöf CGH. Infrequent or non-response to oral sumatriptan does not predict response to other triptans–review of four trials. Cephalalgia 2006;26:98-106.
51. Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults – overview of Cochrane reviews. Cochrane Database Syst. Rev 2014, 5. CD009108 (2014).
52. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst. Rev 2016, 4. CD008541.
53. [No authors listed] Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N. Engl. J Med 1991;325:316-321.
54. Lipton RB *et al*. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N. Engl. J Med 2019;381:142-149.
55. Lipton RB *et al*. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 2019;322:1887-1898.